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Abstract
Background: Patients with syndromic features frequently suffer from recurrent respiratory infections, but little is
known about the spectrum of immunological abnormalities associated with their underlying chromosomal
aberrations outside the well-known examples of Down and DiGeorge syndromes. Therefore, we performed this
retrospective, observational survey study.
Methods: All members of the European Society for Immunodeficiencies (ESID) were invited to participate by
reporting their patients with chromosomal aberration (excluding Down and DiGeorge syndromes) in combination
with one or more identified immunological abnormalities potentially relating to primary immunodeficiency. An
online questionnaire was used to collect the patient data.
Results: Forty-six patients were included from 16 centers (24 males, 22 females; median age 10.4 years [range 1.0–69.
2 years]; 36 pediatric, 10 adult patients). A variety of chromosomal aberrations associated with immunological
abnormalities potentially relating to primary immune deficiency was reported. The most important clinical presentation
prompting the immunological evaluation was ‘recurrent ear-nose-throat (ENT) and airway infections’. Immunoglobulin
isotype and/or IgG-subclass deficiencies were the most prevalent immunological abnormalities reported.
Conclusions: Our survey yielded a wide variety of chromosomal aberrations associated with immunological
abnormalities potentially relating to primary immunodeficiency. Although respiratory tract infections can often
also be ascribed to other causes (e.g. aspiration or structural abnormalities), we show that a significant
proportion of patients also have an antibody deficiency requiring specific treatment (e.g. immunoglobulin
replacement, antibiotic prophylaxis). Therefore, it is important to perform immunological investigations in
patients with chromosomal aberrations and recurrent ENT or airway infections, to identify potential
immunodeficiency that can be specifically treated.
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Background
‘Syndromic’ patients frequently suffer from recurrent re-
spiratory infections; it is a major cause of morbidity and
mortality in this patient group. However, in these patients
immunological work-up is often not performed because
an immunodeficiency is not suspected. The infections are
often ascribed to food and saliva aspiration [1], structural
abnormalities of the upper respiratory tract, neuromuscu-
lar problems, malnutrition or institutionalization. Besides,
other problems are often more prominent than the recur-
rent infections. This may lead to underdiagnosis of ‘syn-
dromic immunodeficiency’. However, identification of an
underlying immune defect may be therapeutically action-
able, which in turn may improve the quality of life in these
patients: for instance hypogammaglobulinemia can be
treated with immunoglobulin replacement [2, 3]. In
addition, information regarding genes critical for the
development and functioning of the immune system may
be gained by analyzing the precise chromosomal defect
and the concomitant immunological phenotype.
Several primary immunodeficiency (PID) disorders
have been identified and increasingly their genetic back-
grounds have been unraveled [4]. Syndromes with
chromosomal abnormalities of number or structure are
considered as a distinct group within PID [5]. Clear
examples are Down syndrome (trisomy 21) [6] and
DiGeorge syndrome (22q11 deletion) [7]. Also, Turner
syndrome [8] and Wolf-Hirschhorn syndrome [9] are
known to be associated with immunodeficiency. In the
past ten years, thirteen cases, three patient series and
two families with other chromosomal aberrations and
immunological abnormalities have been described in the
literature [10–27]. There is one study that screened pa-
tients with dysmorphic disorders for immune defects.
They showed a high incidence of immunodeficiency in
this population (23 out of 29 patients had one or more
defects); however, they also included 11 patients with
Down syndrome [28]. We hypothesize that in patients
with chromosomal aberrations, other than the well-
known Down and DiGeorge syndromes, concomitant
‘syndromic’ immunodeficiency may be underdiagnosed.
To unequivocally prove this, a large case–control study
would be needed; this is not really feasible. To explore
this further, we performed a retrospective, observational
survey study.
Methods
An email message with the proposal to participate in a
survey study was sent out to all members of the European
Society for Immunodeficiencies (ESID) to identify as many
patients known to ESID members as possible with a
chromosomal aberration in combination with one or more
identified immunological abnormalities relating to PID.
Exclusion criteria were trisomy 21 (Down syndrome) and
22q11 deletion (DiGeorge syndrome), because the im-
munological abnormalities in these syndromes have been
described in detail before [6, 7]. Those ESID members
who agreed to participate in the study were requested to
complete an online questionnaire for each of their eligible
patients (Additional file 1). The patients were identified by
physician recall. The answers to the questionnaires were
encrypted and saved on a protected server; these data did
not contain any information that enabled identification of
the identity of the patients. Clinical characteristics and
identified immunological abnormalities were reported.
Age-matched reference values were used for interpret-
ation of immunoglobulin levels and lymphocyte subpopu-
lation counts; values below the age-matched reference
values were scored as ‘low’ [29–31]. For the interpretation
of the vaccine responses (i.e. before and after diagnostic
vaccination with Tetanus and PneumoVax® or Pneumo(-
vax)23®) reference values from the laboratory performing
the tests were used. For responses to Pneumovax® or
Pneumo(vax)23® measured by serotype, a titer ≥1 IU/ml
per serotype was considered to be a sufficient response. If
only total IgG for S. pneumoniae was tested, a >4 fold
increase of titer was considered as a positive response.
Additional immunological tests were performed judged
necessary by the treating physician and are therefore only
available for some patients. Lymphocyte function tests in-
cluded in vitro T lymphocyte proliferation tests (to Conca-
navalin A (ConA), phytohaemagglutinin (PHA), pokeweed
mitogen (PWD) and Staphylococcus aureus enterotoxin A
(SAE)), natural killer (NK) cell and cytotoxic T cell toxicity
(in vitro stimulated CD107a degranulation). Granulocyte
function tests included oxidative burst, the quantitative
nitroblue tetrazolium dye reduction (NBT) test and
phagocytosis test (cells Escherichia coli opsonised). For
these additional immunological test (e.g. lymphocyte and
granulocyte function tests), the laboratory-specific refer-
ence values were used. Furthermore, we asked all the par-
ticipating centers to provide us with the number of
patients with chromosomal aberrations who had under-
gone an immunological evaluation but were subsequently
found not to have an immunological abnormality. This
was also based on physician recall. Descriptive statistics
were performed. The International System for Human
Cytogenetic Nomenclature 2013 (ISCN) was used for
cytogenetic nomenclature [32]; an overview is given as a
group, and in relation to the specific chromosomal aberra-
tions concerned. The Medical Ethical Committee Brabant
approved of the study procedures.
Results
Fifty-two patients from 16 different centers distributed
globally were reported. Six patients had to be excluded
because they did not meet the inclusion criteria: 3 pa-
tients did not have a confirmed chromosomal aberration,
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1 patient with Rubinstein-Taybi Syndrome (no chromo-
somal aberration, only single gene mutation), 1 patient
with suspected Kabuki Syndrome (no genetic diagnosis)
and 1 patient with Rothmund-Thomson Syndrome (no
chromosomal aberration, only single gene mutation).
Three other patients did not have an immunodeficiency,
these were 3 related patients with familial t (12;14).
An overview of the excluded patients is presented in
Additional file 2.
The 46 included patients consisted of 24 males and 22
females with a median age of 10.4 years at the moment
of reporting (range 1.0–69.2 years; 36 pediatric and 10
adult patients). Two families were reported: patients 17
and 20 are related, as well as patients 18 and 19 (they
are also related to the excluded patients 2, 3 and 4, see
Additional file 2). Fifteen of these 46 included patients
have been published before and publication of two pa-
tients is currently in press (for details see Table 1).
Seven out of the total 16 centers provided the number
of patients with chromosomal aberrations who had
undergone an immunological evaluation but were subse-
quently found not to have an immunological abnormality.
Together, they reported 27 patients with immunological
abnormalities in this survey; they also reported 63 patients
with chromosomal aberrations in whom immunological
assessment revealed no abnormality. Thus, of these cen-
ters 30 % of the patients with chromosomal aberrations
who underwent immunological evaluation were diagnosed
with some form of primary immunodeficiency.
Symptoms indicative of PID can be divided into eight
different clinical presentations [29]; ‘recurrent ear-nose-
throat (ENT) and airway infections’ were most com-
monly reported in this cohort (in 43/46 patients). In 31/
46 patients, ‘recurrent ENT and airway infections’ was
reported as the clinically most important presentation.
Other PID-related manifestations reported as the most
important clinical presentation include ‘auto-immune or
chronic inflammatory disease; lymphoproliferation’(n =
5); ‘failure to thrive from early infancy’ (n = 4); ‘unusual
infections or unusually severe course of infections’(n =
3); ‘recurrent pyogenic infections’ (n = 2) and ‘recurrent
infections with the same type of pathogen’(n = 1). The
most common syndromic-related manifestations were:
developmental delay (n = 37), ataxia, paresis or other
motor disability (n = 16), dysmorphic features (n = 31),
microcephaly (n = 11), growth retardation (n = 19),
atopic eczema (n = 8), hair and/or nail abnormalities
(n = 1) and hypopigmentation (n = 1). A detailed overview
of the clinical findings is shown in Table 1.
Antibody deficiency was the most common immuno-
logical defect identified. Of 33 patients reported to have
low immunoglobulin isotype(s), 20 had low IgG (Fig. 1).
Nine patients had low IgG with completely absent IgA
and 8 patients had low IgG in combination with low
IgM. IgG subclass deficiency was identified in 18 pa-
tients, of which 15 had concomitant low total immuno-
globulin isotype(s) and 3 did not. Vaccine responses
were tested in 32/46 patients and were found insufficient
in 18 patients: 16/18 were insufficient for pneumococcal
polysaccharide vaccine. Four patients (no. 2, 22, 23 and
24) showed normal antibody production after diagnostic
vaccination despite low serum immunoglobulins. For
patients 23 and 24, however, the decreased response was
based on total IgG for S. pneumoniae. Responses to live
vaccines were not documented; no unfavorable out-
comes of natural chickenpox infection were reported.
18/46 patients were treated with immunoglobulin re-
placement. The indication of immunoglobulin replace-
ment therapy was based on clinical grounds, as judged
by the treating physician. In 2 patients lymphopenia was
reported; one of them was neutropenic as well. Lympho-
cyte subpopulations (CD3, CD4, CD8, CD19 and CD16/
56) were determined in 36 patients; in 16 a decreased
count of ≥1 (sub)populations was reported. In 11 pa-
tients more extensive B cell subpopulations were deter-
mined and in 7 patients extensive T cell subpopulations
(protocols differed per patient). In 1 patient total ab-
sence of B lymphocytes was reported (patient number 5;
trisomy 13). Lymphocyte and granulocyte function tests
were performed in 11 and 11 patients, respectively; in 2
decreased lymphocyte as well as granulocyte function
was reported (patients 2 and 3). A detailed overview of
the immunological and other laboratory findings is pre-
sented in Table 2 and Additional file 3.
Discussion
Our call identified 46 patients with chromosomal aberra-
tion associated with immunodeficiency, the largest co-
hort reported in the literature so far (42 isolated cases,
and twice 2 patients from the same family). Based on
data from 7/16 participating centers, up to one third of
patients with chromosomal aberrations and recurrent in-
fections may have some form of primary immunodefi-
ciency. Because the patients in this study were identified
by physician recall, reporter bias is possible. However,
the relative number is much higher than the 6 % found
in a cohort of 259 ‘normal’ children screened for im-
munological abnormalities because of recurrent infec-
tions by Brodszki et al. [33]. The most common clinical
presentation in our cohort was ‘recurrent ENT and air-
way infections’, which triggered their physician to per-
form immunological investigations. Not surprisingly,
these were mostly ‘predominantly antibody deficiencies’
[34] ranging from IgG-subclass deficiency and/or poly-
saccharide antibody deficiency to severe hypogammaglo-
bulinemia or even agammaglobulinemia in one patient.
While this study may have limitations inherent to a
retrospective, observational survey (e.g. recall bias;
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Table 1 Clinical characteristics of the included patients
Nr Sex Age (yrs)1 Genetics Immunological presentation2 Other clinical presentations3 Other symptoms
1 M 15.2 46, XY, dup(6) (p12.2p21.31) Airways Developmental delay
Dysmorphic features
Microcephaly
Prematurity 36 weeks
Tracheostomy
Feeding difficulties
Infantile pyloric stenosis
Pulmonary congestion
Intractable diarrhoea
2(a) M 3.4 46, XY.ish der(16)t(16;19) (p13.3;p13.3)
arr[hg19] 16p13.3(106 271–1 024 153)x1,
19p13.3 (327 273–6 887 622)x3
Failure to thrive Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Microcephaly
Growth retardation
Bilateral inguinal hernia
Horse shoe kidney
Hypospadia, hydrocele
Maldescensus testis
3(a) M 9.4 46, XY.ish der(14)t(14;19) (p11.2;p13.2) de
novo; arr[hg19] 19p13.3p13.2(90 897–7
300 043)x3
Unusual infections Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Microcephaly
Growth retardation
Bilateral incarcerated inguinal
hernia
Congenital hip dysplasia
Perineal hypospadia/penoscrotal
fistula
Severe osteopenia
Sensorineurinal hearing loss
Epilepsy
4 M 5.6 46, XY, del(18) (p11.2) Airways Ataxia, paresis or other motor
disability
Growth retardation
na
5 M 12.0 47, XY, +13 Airways Developmental delay
Growth retardation
Sepsis
Seizures
Gastroesophageal reflux disease
Loss of vision
6 F 6.1 46, XX, del(16) (p11.2) Airways Developmental delay
Dysmorphic features
Obesity
Autism
BCGosis
7 M 5.1 46, XY, del(2) (q33.2) AI disease Developmental delay
Dysmorphic features
Cleft palate
PDA
Splenomegaly
Auto-immune hemolytic anemia
8 M 1.0 No full karyotype available
Array CGH : gain of 144kB in 9p24.3 and loss
of 15MB in 10q26.11.q26.3
Unusual infections Developmental delay
Dysmorphic features
Microcephaly
Growth retardation
Duodenal atresia
PDA
Micropenis, gonadal agenesia
9 F 5.2 46, XX, del(18) (q22) AI disease Developmental delay
Dysmorphic features
Auto-immune polyendocrine
syndrome type II with:
Thyroiditis
Vitiligo
Pernicious anemia
Type 1 diabetes mellitus
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Table 1 Clinical characteristics of the included patients (Continued)
10 F 1.4 46, XX, arr[hg19] 16p11.2
(29, 567, 295-30, 177, 916)x1 dn
Failure to thrive Developmental delay
Growth retardation
Recurrent fever
11 F 69.2 45, X Airways Dysmorphic features
Growth retardation
Schwannoma
Hearing loss
12 F 6.5 45, X[42]/47, XXX [8] Airways Developmental delay
Growth retardation
Currarino syndrome
13 F 41.6 45, X Unusual infections Growth retardation na
14 M 20.1 46, XY, der(X)t(X;18) (q28;q23)
(MECP2 duplication)
Airways Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Vitiligo
Bronchiectasis
Small intestinal villous atrophy
15(b) M 7.5 46, XY, r(18)(p11.2q23) [97]/45, XY, -18 [3] Airways Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Microcephaly
Growth retardation
ASD II, VSD
Micropenis
16(c) F 47.7 arr[hg19] 11q24.2q25
(126, 074, 297-134, 927, 114)x1
Airways Developmental delay
Dysmorphic features
Atopic eczema
VSD
Infertility
HPV associated giant condylomata
Hypothyroid
Idiopathic angio-edema
Severe asthma
Hypersplenism
Obesity, type II diabetes
Bronchiectasis
17(d) M 22.3 46, XY, der(18)t(10p;18q) with 18q22.3–q23
deletion and partial trisomy of 10pter
Airways Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Growth retardation
Hypothyroid (subclinical)
Pulmonary valve stenosis
18(e) F 29.3 46, XX, t(12;14) (p11.2;q13) AI disease Atopic eczema Samter's triad*
ALL
Migraine
Recurrent herpes labialis
HPV associated condylomata
Multiple allergies
19(e) F 4.9 46, XX, t(12;14) (p11.2;q13) Airways None na
20(d) F 28.2 46, XX, der(18)t(10p;18q) with 18q22.3–q23
deletion and partial trisomy of 10pter
Airways Ataxia, paresis or other motor
disability
Dysmorphic features
Atopic eczema
Thymus hyperplasia
Atopy
Polyarticular JIA
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Table 1 Clinical characteristics of the included patients (Continued)
21 F 31.3 46, XX, arr[hg19] 15q25.2
(83, 214, 012-84, 776, 990)x1
Airways None Allergy
Epilepsy
Asthma
Cholesteatoma
Recurrent monoarthritis
22 M 34.3 46, XY, inv(10)(q21q23) AI disease None Asymptomatic
23(f) F 6.9 46, XX, del(19)(p13.13) Airways Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Microcephaly
Growth retardation
IUGR
Epilepsy
24(f) M 9.6 46, XY, r(18) AI disease Developmental delay
Dysmorphic features
Growth retardation
Hypopigmentation
Panniculitis with lipodystrophy
Auto-immune hypothyroidism
Vitiligo
Chronic urticaria
Subaortic stenosis
25(g) M 16.8 46, XY, der(11)dup(11) (q22q23)del(q24.3) Airways Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Atopic eczema
Hair and/or nail abnormalities
na
26 M 3.7 No full karyotype available
arr[hg19]11p12-p11.12 (38.090.281-49.257.082)x1
Airways Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Defective absorption folinic acid
27 F 10.3 46, XX, del(11)(q11) Failure to thrive Developmental delay
Dysmorphic features
Growth retardation
Atopic eczema
na
28 F 5.9 49, XXXXX Pyogenic infections Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
PS and ASD
Hypermobility
Radio-ulnar synosthosis
29 M 15.1 46, XY.ish del(X) (p11.3p11.3)
(RP4-628F15+, RP11-245M24 dim, RP6-99M1-,
RP4-689N3-, RP11-1409+)mat
Failure to thrive Developmental delay
Microcephaly
Growth retardation
Visual impairment
Retinitis pigmentosa
30 M 9.4 46, XY, r(6) Airways Developmental delay
Dysmorphic features
Microcephaly
Growth retardation
Gastro-oesofageal reflux
Dilated cardiomyopathy and
small VSD
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Table 1 Clinical characteristics of the included patients (Continued)
31(h) F 12.8 46, XX, del(18)(p11.1) Airways Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Growth retardation
Type I diabetes mellitus
Growth hormone deficiency
Autoimmune thyroiditis
Pectus excavatum
Retrognathia with absent maxillary
chondyles
32 M 6.8 46, XY, del(7)(q22.3 q31.3) Airways Developmental delay
Dysmorphic features
na
33 F 14.7 47, XX, +der(22)t(11;22) (q23;q11) mat
(partial trisomy 11q)
Airways Developmental delay
Ataxia, paresis or other motor
disability
Palatoschizis, preauricular tags
Anus atresia
Urolithiasis
34 F 7.9 46, XX.arr snp 2p23.1 (SNP_A-2078092->
SNP_A-2248377)x1 mat
Same pathogen Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Mitochondrial dysfunction
Acracyanosis
Bronchiectasis
Hyposplenia
35 M 11.3 46, XY.arr[hg19] 3p14.3 (57, 994, 310-58,
071, 249)x1 pat
Airways Developmental delay
Dysmorphic features
Submucosal palatal schisis
Transient neonatal macroglossi
Hepatosplenomegaly
36 F 6.8 45, X Airways None na
37 F 20.2 46, XX, der(2)t(2;10)(q37.3;q26.3)mat.arr
snp 2q37.2q37.3(SNP_A-1957498->
SNP_A-2027809)x1,10q26.3 (SNP_A-2264115->
SNP_A-1934598)x3
Airways Developmental delay
Ataxia, paresis or other motor
disability
Autistiform developmental delay
Splenomegaly
Cytopenias
Granulomata
Gastroparesis
Obesitas
38(i) M 6.5 49, XXXXY Airways Developmental delay
Dysmorphic features
na
39(i) M 10.6 49, XXXXY Airways Developmental delay
Dysmorphic features
na
40(i) M 14.6 49, XXXXY Airways None na
41(i) M 13.3 49, XXXXY Airways Developmental delay
Dysmorphic features
na
42(i) M 11.7 49, XXXXY Airways Developmental delay
Dysmorphic features
Atopic eczema
na
43 M 12.2 47, XYY, dup(22) (q11.21) Pyogenic infections Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Microcephaly
Asthma
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Table 1 Clinical characteristics of the included patients (Continued)
44 F 3.8 46, XX.arr snp 1q44 (SNP_A-2136114->
SNP_A-4223408)x1 dn, 11p11.2p11.12
(SNP_A-1817808->SNP_A-4198132)x3 pat
Airways Developmental delay
Dysmorphic features
Microcephaly
Growth retardation
Atopic eczema
Epilepsy
Rocker bottom foot
Cow’s milk allergy
Feeding difficulties
45 F 6.7 46, X, idic(X) (p11.21).arr snp 22q11.21
(SNP_A-2108791->SNP_A-2160861)x3 mat,
Xp22.33p11.21(SNP_A-4207883->2247707)x1
dn, Xp11.21q28(SNP_A-4201150->
SNP_A-2267820)x3 dn
Airways Developmental delay
Growth retardation
Prematurity; gestational age
30 weeks
Bone anchored hearing aid
Periorbital hemangioma
46 F 12.9 46, XX, arr cgh 16p13.11p13.12
(14, 687, 636-16, 452, 200) x3.
Airways Developmental delay
Ataxia, paresis or other motor
disability
Dysmorphic features
Microcephaly
Growth retardation
Atopic eczema
Severe scoliosis
Seizures
Myopathy of unknown etiology
Chronic progressive external
ophthalmoplegia
Contractures; wheelchair bound
Headings: Nr = patient number; 1at the time of reporting; 2most prominent clinical immunological presentation; 3other clinical presentations as requested in the survey (Additional file 1)
Patients: (a) previously published in Seidel MG, Duerr C, Woutsas S, et al. J Med Genet 2014;51:254–263, (b) previously published in Celmeli F, et al. J Investig Allergol Clin Immunol. 2014;24(6):442–4, (c) previously
published in Seppänen et al. J Clin Immunol 2014;34:114–118., (d) family members and previously published in Dostal et al. International Journal of Immu-genetics 2007;34: 143–147 : patient 17 as IV:4 and patient 20
as IV, (e) family members, together with excluded patient 2, 3 and 4, (f) publication in press, Calvo Campoverde K, et al. Allergologia et Immunopathologia 2016, (g) previously published in Fernandez-San Jose C, J
Paediatr Child Health 2011;47(7):485–6, (h) previously published in Browning MJ, J Investig Allergol Clin Immu-l 2010;20(3):263–266, (i) previously published in Keller MD, et al. Am J Med Genet C Semin Med
Genet. 2013;163C(1):50–4
Clinical presentations: Airways = Recurrent ENT and airway infections; FTT = failure to thrive from early infancy; unusual infections = unusual infections or unusually severe course of infections; AI disease = autoimmune
or chronic inflammatory disease, lymphoproliferation; pyogenic infections = recurrent pyogenic infections; same pathogen = recurrent infections with the same type of pathogen (de Vries E. Clin Exp
Immunol 2012;167(1):108–19.)
Other abbrevations: ALL acute lymphatic leukemia, ASD atrial septum defect, BCG Bacillus Calmette-Guérin, F female, HPV human papilloma virus, IUGR intra uterine growth retardation, JIA juvenile idiopathic arthritis, M
male, na not available, PDA patent ductus arteriosus, PEG percutaneous endoscopic gastrostomy, PS pulmonary stenosis, VSD ventricular septum defect, yrs: years
* Samter’s triad: asthma, aspirin and NSAID sensitivity, and nasal/ethmoidal polyposis
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Fig. 1 Levels of immunoglobulin isotypes. Every dot represents a patient. The bold black line is the lower limit of normal according to age-matched
reference values (ref de Vries E. Clin Exp Immunol 2012;167(1):108–19.). a: IgG in g/L. b: IgA in g/L; two values > 2.0 g/l are not displayed in the graph.
c: IgM in g/L
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Table 2 Results of immunological and other diagnostic tests in the included patients. A: Immunological screening tests
Nr NP LP ↓G ↓A ↓M ↓IgG subclass Lymphocyte subsets Resp TV Resp P L function G function
1 - - + +* - na ↑ aCD3, ↑ aCD3CD4 ↓ ↓ na na
2(a) - - + - + + IgG1, IgG3 ↓ aCD3, ↓ a smB nl nl ↓ NK toxicity Oxidative burst
borderline ↓
In vitro lymphocyte
proliferation: nl
3(a) - - - - - - Borderline ↓ a smB nl nl ↓ vitro lymphocyte
proliferation decreased from
7 years on: SEA
Moderate ↓
oxidative burst
4 - - - + - na na na nl na na
5 - - + +* + + IgG1, IgG2,
IgG3
Absence of CD19 cells na na In vitro lymphocyte
proliferation: nl
na
6 - - - +* - - ↑ aCD3, ↑ aCD3CD4, ↑ aCD19 nl nl na nl
7 - - - +* - na ↓ aCD3, ↓ aCD3CD8 ↓ aCD19 ↓ na na na
8 - - + +* - na nl na na na na
9 - - - - - - ↑ aCD16/56 ↓ na nl na
10 - - - - - na ↑ aCD3, ↑ aCD19, ↑ aCD16/56 nl na Thymic function: nl na
11 - - + - - na ↓ aCD3CD8, ↓ aCD19, ↑
aCD16/56
na nl na nl
12 - - + + - na ↑ aCD3, ↑ aCD3CD4, ↑ aCD19 nl na na na
13 + + + - - na ↓ aCD3CD4, ↓ aCD19, ↓
aCD16/56, ↑ aCD3CD8
na na na na
14 - - - + + + IgG2, IgG4 nl na ↓(j) na na
15(b) - - - - + - nl na na nl nl
16(c) - - + + - + IgG1, IgG2,
IgG4
↓ aCD3, ↓ aCD3CD4, ↓
aCD19, ↓ aCD16/56
na na na na
17(d) - - - +* - +** IgG2, IgG4 nl na na na na
18(e) - - + - - + IgG1, IgG2,
IgG4
↓ aCD19, ↓ aCD16/56 na na na na
19(e) - - + +* - + IgG1 na na na na na
20(d) - - - +* - + IgG4 ↓ aCD16/56 na na na na
21 - - - - - + IgG3, IgG4 ↓ aCD19 cells, slightly ↓ aMZ-
like B, ↑ aCD3, ↑ aCD3CD8
nl nl nl na
22 - + + + + - ↓ aCD3, ↓ aCD3CD4, ↓
aCD3CD8, ↓aCD19 cells (BM)
nl nl na na
23(f) - - + + - + IgG1, IgG2,
IgG4
↓ aCD3CD4, ↓ aCD16/56 nl nl(j) ↓ In vitro lymphocyte
proliferation: PHA = 85 %,
PWD = 72 %, ConA = 39 %
na
24(f) - - + +* - +*** IgG2, IgG3,
IgG4
↓ aCD3CD8 nl nl(j) ↓ In vitro lymphocyte
proliferation: PHA = 92 %,
PWD = 87 %, ConA = 28 %
na
25(g) - - + + + na na nl ↓ ↓ In vitro lymphocyte
proliferation: PHA
na
26 - - + - + + IgG1, IgG3 na na ↓ na na
27 - - - - - - ↓ aCD3, ↓ aCD3CD4, ↓
aCD3CD8, ↓ aCD19, ↓ aCD16/
56
↓ ↓ ↓ In vitro lymphocyte
proliferation: PHA
na
28 - - - + + na ↑ aCD3, ↑ aCD3CD4, ↑
aCD3CD8, ↑ aCD19
nl nl na nl
29 - - - - - - ↑ aCD3CD8, ↑ aCD19 nl ↓ na nl
30 - - - - + na ↓ aCD3, ↓ aCD3CD8 cells, ↑
aCD19
nl ↓ na nl
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reporting bias; convenience sampling), these findings
suggest that 'syndromic immunodeficiency’ may be
under-diagnosed.
A previous study in patients with dysmorphic features
found low CD19+ and CD16+ and/or CD56+ cells as the
most frequent immunological abnormalities, followed by
low immunoglobulins [28]. However, in contrast to our
survey this study also included a lot of patients with
Down syndrome (11/29 patients) who are known to have
lower CD19+ and CD3−CD16+ and/or CD56+ cells [6],
precluding an appreciation for the possibility of under-
lying immunodeficiency in patients with non-Down,
chromosomal syndromes. Until now, no other cohorts of
patients with different chromosomal aberrations associ-
ated with immunological abnormalities have been de-
scribed. The chromosomal aberrations described in our
study may provide insight regarding novel genes in-
volved in the immune system, either located directly
within or adjacent to the anomalous loci. Several of the
cytogenetic abnormalities in our patients have been
linked to immunodeficiency or -dysregulation in the
literature before.
The largest family in our cohort consists of 5 affected
patients with 46, XX, t (12;14) (p11.2;q13) (patients 18,
19 and excluded patients 2, 3 and 4). Only two had
immunodeficiency (patients 18 and 19), both with low
IgG-levels and one with additional IgA-deficiency and
decreased numbers of CD19+ and CD3−CD16+and/
orCD56+ cells. All patients in this family suffered from
atopy, asthma and/or allergy (some with anaphylaxis);
two developed acute lymphatic leukemia. A candidate
gene located on chromosome 14q13 is nuclear factor of
kappa light chain gene enhancer in B cells inhibitor
alpha (NFKBIA) (OMIM 164008). NFKBIA inactivates
NF-kappa-B by trapping it in the cytoplasm. Functional
impairment of NFKBIA can result in increased activa-
tion of the NF-kappa-B pathway leading to immune dys-
regulation [35].
The other family in our cohort consists of two cousins
with an unbalanced translocation t (18q;10p), namely
Table 2 Results of immunological and other diagnostic tests in the included patients. A: Immunological screening tests (Continued)
31(h) - - - + - + IgG2 ↑ aCD3, ↑ aCD3CD4,
↑ aCD3CD8, ↑ aCD19
nl ↓ na nl
32 - - - + + na ↑ aCD19 nl nl na nl
33 - - - - - + IgG1 na na nl na na
34 - - - - - - nl na ↓ na nl
35 - - - + - + IgG2 nl na ↓ na na
36 - - + + - na na na na na na
37 - - + + + + IgG1, IgG2 ↓ aCD3, ↓ aCD3CD8, ↓
aCD19, ↓ aCD16/56 cells,
↓ a memB
na na na na
38(i) - - + - - na na na ↓ na na
39(i) - - na na na na ↑ aCD3CD4 na ↓ na na
40(i) - - - - - na ↑ aCD3, ↑ aCD3CD4 na ↓ na na
41(i) - - - - - na na na ↓ na na
42(i) - - - - - - ↑ aCD3, ↑ aCD3CD4, ↑
aCD19, ↑ aCD16/56
na ↓ na na
43 - - + + - + IgG2 ↑ aCD3, ↑ aCD3CD4, ↑
aCD3CD8, ↑ aCD 19
nl ↓ na na
44 - - - - - + IgG1 na na na na na
45 - - - + - - na na na na na
46 - - + + + na nl na na na na
Headings: Nr patient number, NP neutropenia, LP lymphopenia,↓G: low IgG,↓A: low IgA,↓M: low IgM.↓IgG subclass: low IgG subclasses, Resp TV response tetanus
vaccine, Resp P response PneumoVax® or Pneumo23®, L function: lymphocyte function tests, G function: granulocyte function tests
Patients: (a) previously published in Seidel MG, Duerr C, Woutsas S, et al. J Med Genet 2014;51:254–263, (b) previously published in Celmeli F, J Investig Allergol
Clin Immunol. 2014;24(6):442–4, (c) previously published in Seppänen et al. J Clin Immunol 2014;34:114–118., (d) family members and previously published in
Dostal et al. International Journal of Immu-genetics 2007;34: 143–147 : patient 17 as IV:4 and patient 20 as IV, (e) family members, together with excluded patient
2, 3 and 4, (f) publication in press, Calvo Campoverde K, et al. Allergologia et Immunopathologia 2016, (g) previously published in Fernandez-San Jose C, J Paediatr
Child Health 2011;47(7):485–6. (h) previously published in Browning MJ, J Investig Allergol Clin Immu-l 2010;20(3):263–266, (i) previously published in Keller MD,
et al. Am J Med Genet C Semin Med Genet. 2013;163C(1):50–4, (j) decreased response to Pneumovax ® or Pneumo23® based on total IgG for S. pneumoniae
* IgA completely absent, ** IgG2 completely absent, ***IgG3 completely absent
Other abbrevations: a absolute cell count, BM bone marrow, CD cluster of differentiation, ConA Concanavalin A, memB memory B cells, MZ marginal zone, na not
available, nl normal, PHA phytohaemagglutinin, PWD pokeweed mitogen, SEA Staphylococcus aureus enterotoxin A, smB switched memory B cells
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t (18q-;10p+) (patients 17 and 20), effectively resulting
in a 18q22.3–q23 deletion and a partial trisomy of
10pter. Both showed IgA-deficiency and IgG-subclass
deficiency (both IgG4 and one also IgG2), and one
showed decreased numbers of CD3−CD16+and/or CD56+
cells. One of the cousins showed diffuse thymic hyperpla-
sia (patient 20) without evidence of developing thymoma.
Although patients with complete 10p trisomy are not re-
ported to have immunodeficiency [36, 37], patients with
terminal deletions of 10p have been reported with IgA-
and IgG-deficiency before [21, 38]. The 18q − syndrome is
associated with IgA-deficiency and other autoimmune or
immunodeficiency diseases, such as common variable im-
munodeficiency (CVID) [39], juvenile rheumatic arthritis
[40], insulin-dependent diabetes mellitus [41], celiac dis-
ease [42] and thyroid hormone abnormalities [43]. This
partly matches the clinical phenotypes of our related pa-
tients. The other patients in our cohort with chromosome
18q aberrations all but one also showed IgA-deficiency
(patients 9, 14, and 20). The two cousins from our study
are part of a Finnish family with t (18q;10p), which was
published in 2007 [20]. All members of this family showed
IgA-deficiency; IgG-subclasses were not tested in the
other family members. The authors hypothesized that the
observed IgA-deficiency may result from haplo-
insufficiency of one or multiple genes located in the
18q22.3–q23 region in possible connection with a larger
polygenic network.
Our cohort contains two patients with ring chromo-
some 18 (one mosaic (patient 15) and one with complete
chromosome 18 deletion (patient 24)) and one patient
with 18p deletion (patient 31). Deletions of chromosome
18p have also been associated with immune-related dys-
function like autoimmune thyroiditis, diabetes mellitus,
IgA deficiency, atopic skin conditions, juvenile rheuma-
toid arthritis [12, 15, 22, 25], and in one patient with
SLE [12]. This matches with our patients: two patients
had an IgA-deficiency and the patient with 18p deletion
had multiple endocrine dysfunctions. However, our pa-
tient with a mosaic form of ring chromosome 18 (46,
XY, r(18) (p11.2q23) [97]/45, XY, -18 [3], patient 15)
showed only low IgM with recurrent respiratory tract in-
fections, as published before [27].
Four of our patients showed chromosome 11q dele-
tions (patients 16, 25, 27 and 33); two of them were pub-
lished before [14, 26]. Terminal deletion of chromosome
11 can cause Jacobsen syndrome [44] and has previously
been associated with hypogammaglobulinemia, pancyto-
penia and low T-helper cell counts [45, 46]. Our patients
with 11q deletion did not show neutropenia or lymphope-
nia, but three of them had both IgG- and IgA-deficiency.
No low T-helper cell counts were reported.
Two centers reported a patient with deletion of
chromosome 16p11.2 (patients 6 and 10). Deletions in
this region of chromosome 16 are associated with intellec-
tual disability, congenital anomalies, obesity, macroceph-
aly, and autism [47]. This matches the clinical picture of
one of our patients. Both patients showed only minor im-
munological abnormalities: IgA deficiency and global lym-
phocytosis. Recently, single nucleotide polymorphisms at
the fused-in-sarcoma (FUS)/integrin CD11b (ITGAM)
locus at 16p11.2 were associated with CVID phenotypes
[48]. In the literature, there is also a report of an autistic
girl with a 16p11.2 deletion who also had severe combined
immunodeficiency (SCID) caused by Coronin-1A defi-
ciency (also located at 16p11.2) [49]. Coronin-1A is essen-
tial for development of a normal peripheral T cell
compartment in mice as well as men [33, 50]. However,
this girl had, in contrast to our patient, next to the
16p11.2 deletion, also a 2 bp deletion of the Coronin-1A
gene on the other (paternal) allele.
Several patients with X-chromosome aberration were
included. Turner syndrome (45, X) is known to be asso-
ciated with immunodeficiency [5, 8], but with different
clinical presentations. Our four Turner patients (patients
11, 13 and 36, and patient 12 with mosaicism Turner)
also showed a variety of immunological abnormalities.
The relationship, if any, between the immune defects in
Turner syndrome and those in established X-linked PID
remains unknown. Additionally, 5 boys with 49, XXXXY
(patients 38, 39, 40, 41 and 42) and 1 girl with 49,
XXXXX (patient 28) were reported. The 49, XXXXX girl
presented with pyogenic infections and low IgG and
IgM levels, but with normal granulocyte levels and func-
tion. The 49, XXXXY boys all presented with ‘recurrent
ENT and airway infections’, and they all showed impaired
antibody responses to pneumococcal polysaccharide
antigens, as was published before [11].
Conclusion
This retrospective survey demonstrates that patients
with chromosomal aberrations and recurrent infections
may harbor underlying primary immunodeficiencies. By
specifically excluding the syndromic immunodeficiencies
associated with Down and DiGeorge syndromes, we
showed that a diverse spectrum of chromosomal aberra-
tions can be associated with immunological abnormal-
ities. In our cohort antibody deficiency was the most
prevalent; this is important because infectious complica-
tions can be prevented with early interventions like anti-
biotic prophylaxis or immunoglobulin replacement
treatment in these patients. To assess whether this asso-
ciation is a truly causal relation, a large case–control
study would be needed; this is not really feasible. And of
course, our survey results do not negate other contribut-
ing factors (e.g. aspiration; abnormal anatomy) in the
development of recurrent ENT and airway infections in
these patients. Nonetheless, our findings suggest it is
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important to consider immunological investigations in
patients with chromosomal aberration and recurrent
infections.
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